Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 399-411

  Mello Grand, Maurizia ^a   Singh, Vijay ^a   Ghimenti, Chiara ^a   Scatolini, Maria ^a   Regolo, Lea ^b   Grosso, Enrico ^a   Zambelli, Alberto ^b   Da Prada, Gian Antonio ^b   Villani, Laura ^b   Fregoni, Vittorio ^b   Baiardi, Paola ^c   Marsoni, Silvia ^d   Miller, William R ^e   Costa, Alberto ^b,f   Chiorino, Giovanna ^a  

^a Laboratory of Cancer Genomics   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d Southern Europe New Drug Organization Foundation   (Italy)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

Aromatase inhibitors; Breast cancer; Gene expression profiling; Intrinsic resistance; Neoadjuvant treatment; Response prediction

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; LETROZOLE; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; INFLAMMATION; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TUMOR IMMUNITY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; NEOADJUVANT THERAPY; NITRILES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAZOLES;

EID: 77953027846     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0887-y     Document Type: Article

References (34)

1. Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339: 974-984
2. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467
3. Mauriac L, Smith I (2003) Aromatase inhibitors in early breast cancer treatment. Semin Oncol 4(Suppl 14): 46-57 (Pubitemid 37169773)
4. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606
5. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Eng J Med 349: 1793-1802
6. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092 (Pubitemid 38298988)
7. Harada N (1997) Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Mol Biol 61: 175-184 (Pubitemid 27455676)
8. Sun XZ, Zhou D, Chen S (1997) Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J Steroid Biochem Mol Biol 63: 29-36 (Pubitemid 28018134)
9. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ (2003) Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 39: 462-468 (Pubitemid 36173690)
10. Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR (2002) Effect of neoadjuvant treatment with Anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 87: 334-338
11. Milla Santos A, Milla I, Calvo N, Portella J, Rallo L et al (2004) Anastrozole as neoadjuvant therapy for patients with hormonedependent, locally-advanced breast cancer. Anticancer Res 24: 1315-1318
12. Kristensen VN, Sørlie T, Geisler J, Yoshimura N, Linegjaerde OC et al (2005) Effects of Anastrozole on the intratumoral gene expression in locally advanced breast cancer. J Steroid Biochem Mol Biol 95: 105-111 (Pubitemid 41137300)
13. Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C et al (2008) Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancer: tamoxifene agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat 112: 489-501
14. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR et al (2009) Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 27: 1382-1387
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
16. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G et al (2007) CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 1104012-1104021
17. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3
18. Miller WR, Larionov A, Renshaw L, Anderson TJ, White S et al (2007) Aromatase inhibitors-gene discovery. J Steroid Biochem Mol Biol 106: 130-142
19. Scatolini M, Mello Grand M, Grosso E, Venesio T, Pisacane A et al (2010) Altered molecular pathways in melanocytic lesions. Int J Cancer 126: 1869-1881
20. Ochsner SA, Steffen DL, Hilsenbeck SG, Chen ES, Watkins C, McKenna NJ (2009) GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. Cancer Res 69: 23-26
21. Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D et al (2005) Letrozole-, Anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Mol Cancer Res 3: 203-218
22. Hayashi S, Yamaguchi. Y (2008) Estrogen, signaling in cancer microenvironment and prediction of response to hormonal therapy. J Steroid Biochem Mol Biol 109: 201-206
23. Williams C, Edvardsson K, Lewandowski SA, Ström A, Gustafsson JA (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27: 1019-1032 (Pubitemid 351225390)
24. Sismondi P, Biglia N, Ponzone R, Fuso L, Scafoglio C et al (2007) Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes. Maturitas 57: 50-55
25. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB (2006) Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 13: 617-628 (Pubitemid 43886681)
26. Cappelletti V, Gariboldi M, De Cecco L, Toffanin S, Reid JF et al (2008) Patterns and changes in gene expression following neoadjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr Relat Cancer 15: 439-449 (Pubitemid 351880833)
27. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K et al (2007) Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 9: R37 (Pubitemid 350215170)
28. Wang J, Zhang Q, Jin S, Feng M, Kang X et al (2009) Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis. Exp Gerontol 44: 398-405
29. Lin HY, Sun M, Lin C, Tang HY, London D et al (2009) Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alphapositive and -negative breast cancer cells. J Steroid Biochem Mol Biol 113: 182-188
30. Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME et al (2009) The androgen metabolite 5alpha-androstane-3beta, 17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat 115: 289-296
31. Español AJ, de la Torre E, Fiszman GL, Sales ME (2007) Role of non-neuronal cholinergic system in breast cancer progression. Life Sci 80: 2281-2285 (Pubitemid 46818254)
32. Jones MC, Caswell PT, Norman JC (2006) Endocytic recycling pathways: emerging regulators of cell migration. Curr Opin Cell Biol 18: 549-557
33. Stein MP, Dong J, Wandinger-Ness A. (2003) Rab proteins and endocytic trafficking: potential targets for therapeutic intervention. Adv Drug Deliv Rev 55: 1421-1437 (Pubitemid 37464571)
34. Bièche I, Chavey C, Andrieu C, Busson M, Vacher S et al (2007) CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 14: 1039-1052 (Pubitemid 351252435)